Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM)

Price 287.00p on 18-06-2024 at 05:00:07
Change 0.00p 0%
Buy 0.00p
Sell 0.00p
Buy / Sell HCM Shares
Last Trade: Sell 1,050.00 at 287.00p
Day's Volume: 0
Last Close: 287.00p
Open: 0.00p
ISIN: KYG4672N1198
Day's Range 0.00p - 0.00p
52wk Range: 173.60p - 353.00p
Market Capitalisation: £2,450m
VWAP: 0.00p
Shares in Issue: 854m

Recent Trades History Hutchmed (HCM)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,050 287.00p Uncrossing Trade
15:35:08 - 17-Jun-24
Sell* 8 285.00p Automatic Execution
15:26:47 - 17-Jun-24
Sell* 339 285.00p Automatic Execution
15:26:47 - 17-Jun-24
Buy* 1 288.60p Ordinary
14:55:05 - 17-Jun-24
Buy* 6,930 288.5731p Ordinary
14:38:28 - 17-Jun-24
Sell* 1,151 285.04p Ordinary
14:33:11 - 17-Jun-24
Sell* 233 285.00p Automatic Execution
14:29:52 - 17-Jun-24
Sell* 1 285.07p Ordinary
14:13:51 - 17-Jun-24
Buy* 6 285.98p Ordinary
14:13:50 - 17-Jun-24
Buy* 374 285.00p Automatic Execution
14:03:35 - 17-Jun-24

Share Price History for Hutchmed

Time period:
to
Date Open High Low Close Volume

Share News for Hutchmed

Hutchmed celebrates "promising" results for sovleplenib in China

17th Jun 2024 10:32

(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP. Read More

IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506

7th Jun 2024 18:13

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains. Read More

IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar

17th May 2024 17:58

Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid. Read More

Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies

14th May 2024 14:33

(Alliance News) - Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it believes could fill significant clinical gaps. Read More

UK shareholder meetings calendar - next 7 days

3rd May 2024 13:37

Read More

FTSE 100 Latest
Value8,142.15
Change0.00

Login to your account

Forgot Password?

Not Registered